Harmony Biosciences Holdings Inc HRMY

NAS: HRMY | ISIN: US4131971040 26/04/2024

29,32 USD (+1,35%)

(+1,35%) 26/04/2024

Grafiek Harmony Biosciences Holdings Inc

Grafiek Harmony Biosciences Holdings Inc

1 dag1d 1,35%
1 week1w -0,10%
1 maand1m -12,53%
3 maanden3m -9,14%
6 maanden6m 52,71%
1 jaar1j -6,33%
5 jaar5j -20,78%

dinsdag 30 april 2024, 13:30

Kwartaalcijfers (1ste kwartaal)

Harmony Biosciences Holdings Inc in het nieuws

Toon enkel gratis nieuws

16 april 2024 · Harmony Biosciences To Report First Quarter 2024 Financial Results On April 30, 2024 · Persbericht

11 april 2024 · Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize Tpm-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist · Persbericht

3 april 2024 · Harmony Biosciences Initiates Global Phase 3 Registrational Trial (Tempo Study) Of Pitolisant In Patients With Prader-Willi Syndrome · Persbericht

26 maart 2024 · Harmony Biosciences To Participate In 23Rd Annual Needham Virtual Healthcare Conference · Persbericht

28 februari 2024 · Harmony Biosciences To Participate In Upcoming Investor Conferences · Persbericht

21 februari 2024 · U.s. Food And Drug Administration Grants Priority Review To Harmony Biosciences' Application For Wakix® (Pitolisant) In Pediatric Narcolepsy · Persbericht

20 februari 2024 · Harmony Biosciences Receives U.s. Food And Drug Administration Orphan Drug Designation For Pitolisant In Prader-Willi Syndrome · Persbericht

8 februari 2024 · Harmony Biosciences To Report Fourth Quarter And Full Year 2023 Financial Results On February 22, 2024 · Persbericht

8 januari 2024 · Harmony Biosciences Preliminary Unaudited Fourth Quarter And Full Year 2023 Net Product Revenue Increases More Than 30 Percent; Provides 2024 Net Product Revenue Guidance · Persbericht

3 januari 2024 · Harmony Biosciences To Present At The 42Nd Annual J.p. Morgan Healthcare Conference · Persbericht

Profiel Harmony Biosciences Holdings Inc

Gezondheidstechnologie

Medicinale en botanische productie

Werknemers: 221

Aandelen Harmony Biosciences Holdings Inc

Beurswaarde: 1,64 miljard USD

Effecten: 56,79 miljoen

Winst per aandeel (12 maand): PLUS

Koers-winstverhouding: PLUS

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe